DK0662130T3 - Fremgangsmåde til fremstilling af hepatocytvækstfaktor og en cellelinje - Google Patents

Fremgangsmåde til fremstilling af hepatocytvækstfaktor og en cellelinje

Info

Publication number
DK0662130T3
DK0662130T3 DK93921471T DK93921471T DK0662130T3 DK 0662130 T3 DK0662130 T3 DK 0662130T3 DK 93921471 T DK93921471 T DK 93921471T DK 93921471 T DK93921471 T DK 93921471T DK 0662130 T3 DK0662130 T3 DK 0662130T3
Authority
DK
Denmark
Prior art keywords
met
hgf
preparation
antibody
substance
Prior art date
Application number
DK93921471T
Other languages
English (en)
Inventor
Donna L Faletto
Ilan Tsarfaty
Sing Rong
Marianne Oskarsson
Woude George F Vande
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK0662130T3 publication Critical patent/DK0662130T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK93921471T 1992-09-18 1993-09-15 Fremgangsmåde til fremstilling af hepatocytvækstfaktor og en cellelinje DK0662130T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94606192A 1992-09-18 1992-09-18
PCT/US1993/008531 WO1994006909A2 (en) 1992-09-18 1993-09-15 A method of preventing tumor metastasis

Publications (1)

Publication Number Publication Date
DK0662130T3 true DK0662130T3 (da) 1998-08-10

Family

ID=25483898

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93921471T DK0662130T3 (da) 1992-09-18 1993-09-15 Fremgangsmåde til fremstilling af hepatocytvækstfaktor og en cellelinje

Country Status (10)

Country Link
EP (2) EP0805203B1 (da)
JP (2) JP3553936B2 (da)
AT (2) ATE368738T1 (da)
AU (1) AU675968B2 (da)
CA (1) CA2144856A1 (da)
DE (2) DE69334159D1 (da)
DK (1) DK0662130T3 (da)
ES (1) ES2112997T3 (da)
GR (1) GR3026165T3 (da)
WO (1) WO1994006909A2 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
CA2144081C (en) * 1992-09-16 2004-11-30 Filip Roos Protection against liver damage by hgf
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6855685B2 (en) 1995-10-24 2005-02-15 Toshikazu Nakamura Anti-cancer agent
JP3832674B2 (ja) * 1995-10-24 2006-10-11 敏一 中村 抗癌剤
WO1998019696A1 (en) * 1996-11-05 1998-05-14 Smithkline Beecham Corporation Hepatocyte growth factor antagonists
AU1465400A (en) * 1998-11-04 2000-05-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Identification of inhibitors of the hgf-met-upa-plasmin network using a novel cellular assay
IL131142A0 (en) * 1999-07-28 2001-01-28 Rad Ramot Prognosis of breast cancer and other diseases
US7459536B1 (en) 1999-11-09 2008-12-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HGF-SF monoclonal antibody combinations
EP1355921A2 (en) * 2000-06-29 2003-10-29 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
WO2004072117A2 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
KR101254371B1 (ko) 2003-07-18 2013-05-02 암젠 프레몬트 인코포레이티드 간세포 성장인자에 결합하는 분리된 항체
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP1773885B1 (en) 2004-08-05 2010-04-21 Genentech, Inc. Humanized anti-cmet antagonists
KR20130114763A (ko) 2005-03-31 2013-10-18 더 제너럴 하스피탈 코포레이션 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정
SG161281A1 (en) 2005-04-15 2010-05-27 Genentech Inc Hgf beta chain variants
ES2369739T3 (es) * 2006-03-20 2011-12-05 Seikagaku Corporation Agente terapéutico para la artritis reumatoide.
EP2004693B1 (en) 2006-03-30 2012-06-06 Novartis AG Compositions and methods of use for antibodies of c-met
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
EP2635602B1 (en) 2010-11-03 2016-09-07 Argen-X Nv Anti c-met antibodies
JP6173298B2 (ja) * 2011-04-02 2017-08-02 ワシントン ステート ユニバーシティ 治療薬としての肝細胞増殖因子模倣体
RU2013155695A (ru) 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US10450376B2 (en) 2014-09-16 2019-10-22 Symphogen A/S Anti-MET antibodies and compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648273A (en) * 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
GB9003621D0 (en) * 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
DE69133349T2 (de) * 1990-09-14 2004-10-07 Us Health Ein nicht-mitogener kompetitiver hgf-antagonist
ES2181689T3 (es) * 1992-05-18 2003-03-01 Genentech Inc Variantes del factor de crecimiento de hepatocitos.

Also Published As

Publication number Publication date
AU675968B2 (en) 1997-02-27
DE69315440D1 (de) 1998-01-08
DE69315440T2 (de) 1998-07-09
EP0662130B1 (en) 1997-11-26
JPH08504093A (ja) 1996-05-07
WO1994006909A2 (en) 1994-03-31
ES2112997T3 (es) 1998-04-16
EP0805203A1 (en) 1997-11-05
EP0805203B1 (en) 2007-08-01
WO1994006909A3 (en) 1994-05-26
JP2004002440A (ja) 2004-01-08
ATE368738T1 (de) 2007-08-15
AU4855593A (en) 1994-04-12
DE69334159D1 (de) 2007-09-13
EP0662130A1 (en) 1995-07-12
ATE160585T1 (de) 1997-12-15
CA2144856A1 (en) 1994-03-31
JP3553936B2 (ja) 2004-08-11
GR3026165T3 (en) 1998-05-29

Similar Documents

Publication Publication Date Title
DK0662130T3 (da) Fremgangsmåde til fremstilling af hepatocytvækstfaktor og en cellelinje
DE69433406T2 (de) Antikörper gegen cd40
NO2017038I2 (no) Adalimumab - Forlenget SPC
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
MY145191A (en) Human antibodies that bind human il-12 and methods for producing
EP1174148A4 (en) PARENTAL MEDICAL COMPOSITIONS CONTAINING FRAGMENTS OF HUMANIZED MONOCLONAL ANTIBODIES AND METHOD FOR STABILIZING THE SAME
ATE194168T1 (de) Varianten in den leltin domäne von selektin
BR0314369A (pt) Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado
DE69813022D1 (de) Injektor zur behandlung von metallschmelzen mit gasen
DE69301904D1 (de) Zusammensetzung zur behandlung von keratinfasern
FI961380L (fi) Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitamiseksi
DK0504307T3 (da) Fremgangsmåde til behandling af septisk shock
DE69224134D1 (de) Monoklonale Antikörper gegen Hepatitis-C-Virus
DK361282A (da) Fremgangsmaade til fremstilling af o-alkyl-o-carbamoylglycerophosphocholiner
ATE297211T1 (de) Verfahren und zusammensetzung zur behandlung von adenovirale augeninfektionen
DE69527868D1 (de) Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II)
DK119891D0 (da) Forbedringer ved og i forbindelse med magnetisk resonansafbildning
ATE335504T1 (de) Humanisierte antikörper zur erkennung von verotoxin ii sowie zellinie zur herstellung derselben
DE69112392D1 (de) Bcrf1-antagonisten zur behandlung von epstein-barr-virus-infektionen.
FI952779A7 (fi) HCV:n C33-alueen peptidejä, vasta-aineita niitä vastaan ja menetelmiä HCV:n toteamiseksi
EP0642803A3 (de) Tracheostoma-Verschluss.
KR960028933U (ko) 자화수 제조용 물통 속마개
Durand-Charre et al. Structure and Solidification Sequence of Alloyed White Cast Irons.(Synopsis)
DK159280A (da) Fremgangsmaade til styring af kontrasten ved reproduktion saasom rasterreproduktion
ES2030342A6 (es) Procedimiento de obtencion de una fuente de antigeno para el serodiagnostico inmunohistologico de la listerioris.